Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
E-pub ahead of print

Characterisation of vasodilatory responses in the presence of the CGRP receptor antibody erenumab in human isolated arteries

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Monitoring chronic headache and medication-overuse headache prevalence in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Diagnostic delay of cluster headache: A cohort study from the Danish Cluster Headache Survey

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. PACAP27 induces migraine-like attacks in migraine patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Hyperpolarization through ATP-sensitive potassium channels; relevance to migraine pathology

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  2. C-fibers may modulate adjacent Aδ-fibers through axon-axon CGRP signaling at nodes of Ranvier in the trigeminal system

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Exploration of physiological and pathophysiological implications of miRNA-143 and miRNA-145 in cerebral arteries

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Exploration of purinergic receptors as potential anti-migraine targets using established pre-clinical migraine models

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Eloísa Rubio-Beltrán
  • Alejandro Labastida-Ramírez
  • Kristian A Haanes
  • Antoon van den Bogaerdt
  • Ad Jjc Bogers
  • Clemens Dirven
  • Ah Jan Danser
  • Cen Xu
  • Josefin Snellman
  • Antoinette MaassenVanDenBrink
Vis graf over relationer

BACKGROUND: Migraine is associated with activation of the trigeminovascular system, release of calcitonin gene-related peptide (CGRP) and dilation of dural arteries. Novel treatments target calcitonin gene-related peptide or its receptor, which are present in all vascular beds, raising cardiovascular concerns. Erenumab is a human CGRP-receptor antibody approved for the prophylactic treatment of migraine.

METHODS: We characterised the relaxant responses to CGRP in the absence and presence of erenumab (1 μM) in isolated human middle meningeal, internal mammary and (proximal and distal) coronary arteries. Furthermore, in human internal mammary arteries from cardiovascularly-compromised patients, we assessed the pharmacological specificity of erenumab by investigating whether the vasodilatory responses to acetylcholine, sodium nitroprusside, pituitary adenylate cyclase activating polypeptide-38 (PACAP), vasoactive intestinal peptide and nicardipine, along with the vasoconstrictor responses to dihydroergotamine, were modified by erenumab.

RESULTS: Calcitonin gene-related peptide induced concentration-dependent vasodilatory responses in all vessels studied that were significantly antagonised by erenumab. In human internal mammary arteries from cardiovascularly-compromised patients, the responses to acetylcholine, sodium nitroprusside, PACAP, vasoactive intestinal peptide, nicardipine and dihydroergotamine were unaffected by erenumab.

CONCLUSION: Erenumab inhibits calcitonin gene-related peptide-induced vasodilatory responses in human middle meningeal arteries, human internal mammary arteries and human coronary arteries. Moreover, erenumab shows functional specificity as no interaction was observed with the relaxant responses to several vasodilators, nor the dihydroergotamine-dependent vasoconstrictor responses.

OriginalsprogEngelsk
TidsskriftCephalalgia : an international journal of headache
Sider (fra-til)epub
ISSN0333-1024
DOI
StatusE-pub ahead of print - 2019
Eksternt udgivetJa

ID: 58349218